News_Media Center_Shanghai Xihua Scientific Co.,Ltd.

搜索

资讯中心

Current location：

2023
03-28 

Chun Li led the team to visit Xihua

On March 22, 2023, Chun Li, Mayor of Sanming, Fujian Province, together with leaders of other government departments and leaders of Pudong New Area Economic and Information Commission, visited Shanghai Xihua.

Learn more +

2023
03-24 

国家药监局关于发布化学仿制药参比制剂调整程序的公告（2023年第35号）

为进一步完善仿制药参比制剂管理，促进我国仿制药高质量研发，国家药品监督管理局组织制定了化学仿制药参比制剂调整程序（试行），现予发布，自发布之日起施行。

Learn more +

2023
02-21 

Zheyuan Jiang led the team to visit Xihua

On February 17, 2022, Zheyuan Jiang and Wei Xu visited Xihua. Dr. Xing, Chairman of Xihua , and Dr. Gong, CEO of XihuaPharma, together with other relevant department heads, attended the symposium and accompanied them during the visit.

Learn more +

Zheyuan Jiang led the team to visit Xihua

2023
01-20 

Yi Huang led the team to visit Xihua before the Spring Festival

On January 18, 2023, Yi Huang, deputy secretary of the Zhoupu Town Party Committee, together with the Town Peace Office, Zhoudong Police Station and other departments, went to Xihua to carry out pre-holiday safety and stability investigation and visits

Learn more +

Yi Huang led the team to visit Xihua before the Spring Festival

2022
12-22 

Dr. Shen was invited to participate in the 2022 Pudong International Talent Port Forum

On December 7, 2022, the Pudong International Talent Port Sub-Forum with the theme of ‘Talent chain drives industrial chain and innovation chain, Creating Pudong's ace Card’ was successfully held.

Learn more +

Dr. Shen was invited to participate in the 2022 Pudong International Talent Port Forum

2022
11-22 

加快打造全球生物医药研发经济和产业化高地，上海出台政策措施（附图解）

《若干政策措施》提出到2025年，上海全球生物医药研发经济和产业化高地发展格局初步形成，研发经济总体规模达到1000亿元以上，培育或引进100个以上创新药和医疗器械重磅产品，培育50家以上具备生物医药研发、销售、结算等复合功能的创新型总部。

Learn more +

2022
10-27 

The main project of the first phase of Fujian Xixiang production base was officially launched

On October 26, 2022, the main project of the first phase of Fujian Xixiang API and supporting intermediates production base was officially launched in Mingxi, Fujian. Jinsong Xing, Chairman of Shanghai Xihua Scientific Co., Ltd., Ke Zhong, Secretary of Mingxi County Party Committee, Qing Jin, Vice President of Shanghai Construction NO.5 (Group) Co., Ltd. and Eugene Gong, CEO of Shanghai Xihua Pharmaceutical Co., Ltd. / Chairman of Fujian Xixiang Pharmaceutical Co., Ltd. attended the ceremony and delivered speeches. Huawei Chen, Liangfu Chen, Fengyi Chen, Qiang Li, Ting Xu and other county leaders and heads of relevant departments, Shanghai Xihua Scientific Co., Ltd., Shanghai Xihua Pharmaceuticals Co., Ltd., Fujian South Pharmaceutical Co., Ltd., Shanghai Construction NO.5 (Group) Co., Ltd. attended the ceremony.

Learn more +

The main project of the first phase of Fujian Xixiang production base was officially launched

2022
10-24 

The base project of Xihua R&D Headquarters and Industrialization has officially signed

On October 18, 2022, a group of key projects involving multiple high-tech fields held a centralized signing ceremony in Zhoupu Town. Dr. Jinsong Xing, chairman of Xihua, was invited as a representative of the industrial project to complete the on-site signing under the witness of district and town leaders.

Learn more +

The base project of Xihua R&D Headquarters and Industrialization has officially signed

2022
07-14 

Qing Wang visited Xihua for investigation

July 7, 2022 , at about 10 am , Qing Wang, Party Secretary of Zhangjiang Town, and Li Guan, Deputy Mayor of Zhangjiang Town, and several others visited Shanghai Xihua Scientific Co., Ltd. to carry out large-scale investigations named ‘Epidemic, Economy ,Safety’, Xihua General Manager Xiaohang Shen, Executive Vice President Hao Li, Vice President of Operations Lanjin Qu and other representatives accompanied.

Learn more +

Qing Wang visited Xihua for investigation

2022
06-29 

XIHUA holds TCM Groups, Inc. and dedicates to pushing the development of the global pharmaceutical industry

In July 2023, Xihua have completed the acquisition of TCM Groups, Inc. (‘TCM’), USA. And then, as one of subsidiary of XIHUA ,TCM will continue to provide clinical trial research professional services to global pharmaceutical companies.

Learn more +